Short answer
Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders re-elected Dennis M. Lanfear and Mats L. Wahlström as Class III directors through 2029.
Coherus Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders re-elected Dennis M. Lanfear and Mats L. Wahlström as Class III directors through 2029
- Ernst & Young LLP ratified as independent auditor for fiscal year ending December 31, 2026
- Say-on-pay approved with 73,322,772 votes, supporting continued executive compensation program
- Option exercise-price reductions approved narrowly, 45,996,610 votes to 45,362,110
- Equity plan share reserve increased, enabling additional stock-based awards and potential dilution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Coherus Oncology, Inc. 8-K filings
Get the next CHRS 8-K as it lands
Follow CHRS for push alerts, or ask the research agent what this filing means.